Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Retracted: Self-assembled Phenylalanine-α,β-dehydrophenylalanine Nanotubes for Sustained Intravitreal Delivery of a Multi-targeted Tyrosine Kinase Inhibitor.

Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB.

J Control Release. 2016 Sep 10;237:186. doi: 10.1016/j.jconrel.2016.07.039.

2.

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Kadam RS, Van Den Anker JN.

Clin Pharmacokinet. 2016 Sep;55(9):1031-43. doi: 10.1007/s40262-016-0379-2. Review.

PMID:
26979736
3.

Self-assembled phenylalanine-α,β-dehydrophenylalanine nanotubes for sustained intravitreal delivery of a multi-targeted tyrosine kinase inhibitor.

Panda JJ, Yandrapu S, Kadam RS, Chauhan VS, Kompella UB.

J Control Release. 2013 Dec 28;172(3):1151-60. doi: 10.1016/j.jconrel.2013.09.016. Epub 2013 Sep 25. Retraction in: J Control Release. 2016 Sep 10;237:186.

4.
5.

Hypoxia alters ocular drug transporter expression and activity in rat and calf models: implications for drug delivery.

Kadam RS, Ramamoorthy P, LaFlamme DJ, McKinsey TA, Kompella UB.

Mol Pharm. 2013 Jun 3;10(6):2350-61. doi: 10.1021/mp3007133. Epub 2013 May 22. Retraction in: Mol Pharm. 2015 Jul 6;12(7):2559.

6.
7.

Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry.

Tyagi P, Kadam RS, Kompella UB.

PLoS One. 2012;7(10):e48188. doi: 10.1371/journal.pone.0048188. Epub 2012 Oct 31.

8.

Pigmented-MDCK (P-MDCK) cell line with tunable melanin expression: an in vitro model for the outer blood-retinal barrier.

Kadam RS, Scheinman RI, Kompella UB.

Mol Pharm. 2012 Nov 5;9(11):3228-35. doi: 10.1021/mp300305f. Epub 2012 Oct 15.

9.

Transporter targeted gatifloxacin prodrugs: synthesis, permeability, and topical ocular delivery.

Vooturi SK, Kadam RS, Kompella UB.

Mol Pharm. 2012 Nov 5;9(11):3136-46. doi: 10.1021/mp300245r. Epub 2012 Oct 11.

10.
11.

RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide.

Kadam RS, Tyagi P, Edelhauser HF, Kompella UB.

Int J Pharm. 2012 Sep 15;434(1-2):140-7. doi: 10.1016/j.ijpharm.2012.05.025. Epub 2012 May 23.

12.

Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone.

Aquilante CL, Kosmiski LA, Bourne DW, Bushman LR, Daily EB, Hammond KP, Hopley CW, Kadam RS, Kanack AT, Kompella UB, Le M, Predhomme JA, Rower JE, Sidhom MS.

Br J Clin Pharmacol. 2013 Jan;75(1):217-26. doi: 10.1111/j.1365-2125.2012.04343.x.

13.

Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance.

Kadam RS, Bourne DW, Kompella UB.

Drug Metab Dispos. 2012 Jul;40(7):1380-8. doi: 10.1124/dmd.112.044925. Epub 2012 Apr 12.

14.

Hydrophilic prodrug approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.

Malik P, Kadam RS, Cheruvu NP, Kompella UB.

Mol Pharm. 2012 Mar 5;9(3):605-14. doi: 10.1021/mp2005164. Epub 2012 Feb 8. Retraction in: Mol Pharm. 2015 Jul 6;12(7):2558.

15.

Brain mitochondrial drug delivery: influence of drug physicochemical properties.

Durazo SA, Kadam RS, Drechsel D, Patel M, Kompella UB.

Pharm Res. 2011 Nov;28(11):2833-47. doi: 10.1007/s11095-011-0532-4. Epub 2011 Jul 28.

16.

Ocular pharmacokinetics of dorzolamide and brinzolamide after single and multiple topical dosing: implications for effects on ocular blood flow.

Kadam RS, Jadhav G, Ogidigben M, Kompella UB.

Drug Metab Dispos. 2011 Sep;39(9):1529-37. doi: 10.1124/dmd.111.040055. Epub 2011 Jun 14.

17.

Recent advances in ophthalmic drug delivery.

Kompella UB, Kadam RS, Lee VH.

Ther Deliv. 2010 Sep;1(3):435-56. doi: 10.4155/TDE.10.40. Review.

18.

Influence of drug solubility and lipophilicity on transscleral retinal delivery of six corticosteroids.

Thakur A, Kadam RS, Kompella UB.

Drug Metab Dispos. 2011 May;39(5):771-81. doi: 10.1124/dmd.110.037408. Epub 2011 Feb 23.

19.

Sclera-choroid-RPE transport of eight β-blockers in human, bovine, porcine, rabbit, and rat models.

Kadam RS, Cheruvu NP, Edelhauser HF, Kompella UB.

Invest Ophthalmol Vis Sci. 2011 Jul 23;52(8):5387-99. doi: 10.1167/iovs.10-6233. Retraction in: Beebe DC. Invest Ophthalmol Vis Sci. 2015 Mar;56(3):1678.

20.

Synthetic LXR agonist suppresses endogenous cholesterol biosynthesis and efficiently lowers plasma cholesterol.

Pfeifer T, Buchebner M, Chandak PG, Patankar J, Kratzer A, Obrowsky S, Rechberger GN, Kadam RS, Kompella UB, Kostner GM, Kratky D, Levak-Frank S.

Curr Pharm Biotechnol. 2011 Feb 1;12(2):285-92. Erratum in: Curr Pharm Biotechnol. 2016;17(9):846.

21.

Validation of an LC/MS method for the determination of gemfibrozil in human plasma and its application to a pharmacokinetic study.

Rower JE, Bushman LR, Hammond KP, Kadam RS, Aquilante CL.

Biomed Chromatogr. 2010 Dec;24(12):1300-8. doi: 10.1002/bmc.1440.

22.

Nanosized dendritic polyguanidilyated translocators for enhanced solubility, permeability, and delivery of gatifloxacin.

Durairaj C, Kadam RS, Chandler JW, Hutcherson SL, Kompella UB.

Invest Ophthalmol Vis Sci. 2010 Nov;51(11):5804-16. doi: 10.1167/iovs.10-5388. Epub 2010 May 19.

PMID:
20484584
23.

Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve.

Kadam RS, Kompella UB.

J Pharmacol Exp Ther. 2010 Mar;332(3):1107-20. doi: 10.1124/jpet.109.161570. Epub 2009 Nov 19. Retraction in: J Pharmacol Exp Ther. 2015 Feb;352(2):326.

24.

Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation.

Kim ES, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF.

Pharm Res. 2009 May;26(5):1155-61. doi: 10.1007/s11095-009-9835-0. Epub 2009 Feb 5.

PMID:
19194787
25.

Cassette analysis of eight beta-blockers in bovine eye sclera, choroid-RPE, retina, and vitreous by liquid chromatography-tandem mass spectrometry.

Kadam RS, Kompella UB.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):253-60. doi: 10.1016/j.jchromb.2008.12.027. Epub 2008 Dec 24.

PMID:
19117816
26.

Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia.

Kratzer A, Buchebner M, Pfeifer T, Becker TM, Uray G, Miyazaki M, Miyazaki-Anzai S, Ebner B, Chandak PG, Kadam RS, Calayir E, Rathke N, Ahammer H, Radovic B, Trauner M, Hoefler G, Kompella UB, Fauler G, Levi M, Levak-Frank S, Kostner GM, Kratky D.

J Lipid Res. 2009 Feb;50(2):312-26. doi: 10.1194/jlr.M800376-JLR200. Epub 2008 Sep 23.

27.
28.

Subcutaneous phycomycosis.

Chandrasekhar HR, Shashikala PN, Haravi RN, Kadam RS.

Indian J Dermatol Venereol Leprol. 1998 Mar-Apr;64(2):89-90. No abstract available.

Supplemental Content

Loading ...
Support Center